Merck & Company Inc (NYSE:MRK) has ceased discussions to acquire biotechnology firm Revolution Medicines Inc (NASDAQ:RVMD), following a failure to reach an agreement on the company’s valuation.

If you are wondering whether RTX at US$195.93 still makes sense on a valuation basis after its strong run, this article will ...

With so much volatility in the market, it’s a good time for investors to consider stocks that they can hold for the long haul ...

United States equity markets closed lower as sector based movement shaped benchmark direction, reflecting varied participation across exchanges and highlighting structural influences within the ...

It was a night of "Stranger Things" crossovers on "WWE Raw," as well as some terrifying injury scares. While she didn't wrestle, Stephanie Vaquer was seen in a walking boot and was attacked several ...

A federal judge in California on Wednesday voided the Trump administration's move to terminate the Temporary Protected Status of roughly 60,000 immigrants from Honduras, Nepal and Nicaragua, calling ...

Merck is rated a buy, with strong earnings growth, rising cash flow, and balance sheet strength supporting a bullish outlook. Keytruda's double-digit growth and margin expansion drive MRK's profits, ...

Merck (MRK) stock achieved a 5-day winning streak, with total gains during this time reaching 6.9%. The company’s market capitalization has jumped by approximately $17 billion over the past five days, ...

Whales with a lot of money to spend have taken a noticeably bearish stance on Merck & Co. Looking at options history for Merck & Co (NYSE:MRK) we detected 13 trades. If we consider the specifics of ...

On December 12, Morgan Stanley lifted its price target on Merck & Co., Inc. (NYSE:MRK) to $102 from $100. The firm kept an Equal Weight rating on the stock. In its 2026 outlook for the biopharma space ...

About 700 Somali immigrants are currently allowed to live and work in the United States under a program for people fleeing countries in turmoil. By Nicholas Bogel-Burroughs President Trump intends to ...

Merck presents a bullish investment case with strong valuation, improving grades, and a well-supported, growing dividend. MRK's technical setup is positive: price trades above its 30-week EMA, ...